STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

STAAR Surgical Company (NASDAQ: STAA), a leader in developing and marketing Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism, and presbyopia, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.

Chief Financial Officer Patrick F. Williams will represent STAAR in a fireside chat on June 12, 2024, at 8:00 a.m. Eastern Time. The event will be webcast live, with a recording available on STAAR's investor website afterward.

STAAR has been dedicated to ophthalmic surgery for over 40 years, selling over 3 million ICLs in more than 75 countries. Headquartered in Lake Forest, CA, the company operates production facilities in the U.S. and Switzerland.

Positive

• Participation in high-profile Goldman Sachs conference, increasing visibility.
• Live webcast offers transparency and accessibility to investors.
• Strong market presence with over 3 million ICLs sold globally.
• Operational reach in over 75 countries, indicating a strong global footprint.

Negative

• Event participation does not guarantee positive financial impact.
• Potential market volatility around the event date.
• Operational costs for maintaining facilities in multiple locations.

LAKE FOREST, Calif.--(BUSINESS WIRE)-- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45^th Annual Global Healthcare Conference, which will be held in Miami, Florida.

Patrick F. Williams, Chief Financial Officer, will participate in a fireside chat on Wednesday, June 12, 2024, at 8:00 a.m. Eastern Time. A live audio webcast of the session can be accessed at https://investors.staar.com/ or directly here. An archive of the webcast will also be available on STAAR’s investor website following the conference.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL,” which includes the EVO ICL™ product line. More than 3,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: EVOICL.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please visit the Company’s website at www.staar.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605310433/en/

Investors & Media

Brian Moore

Vice President, Investor Relations and Corporate Development

(626) 303-7902, Ext. 3023

bmoore@staar.com

Source: STAAR Surgical Company

FAQ

What event is STAAR Surgical participating in?

STAAR Surgical is participating in the Goldman Sachs 45th Annual Global Healthcare Conference.

When is the STAAR Surgical's fireside chat at the conference?

The fireside chat will take place on June 12, 2024, at 8:00 a.m. Eastern Time.

Where can I access the live webcast for STAAR Surgical's event?

The live webcast can be accessed at https://investors.staar.com/.

What does STAAR Surgical specialize in?

STAAR Surgical specializes in developing and marketing Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism, and presbyopia.

How many ICLs has STAAR Surgical sold?

STAAR Surgical has sold over 3 million ICLs globally.

In how many countries does STAAR Surgical market its lenses?

STAAR Surgical markets its lenses in over 75 countries.